Centre Hospitalier Universitaire Grenoble Alpes

Cegedim: Full year 2022 results

Retrieved on: 
Thursday, March 23, 2023

Corporate and others: 2022 REBIT(1) was a €3.4 million loss, €2.3 million higher than the loss in 2021.

Key Points: 
  • Corporate and others: 2022 REBIT(1) was a €3.4 million loss, €2.3 million higher than the loss in 2021.
  • To the best of the company’s knowledge, there were no events or changes during 2022 that would materially alter the Group’s financial situation.
  • On May 16, 2022, Cegedim Group and social protection companies Malakoff Humanis, Groupe VYV, and PRO BTP Groupe announced that they had finalized the strategic partnership they began negotiating on March 1, 2022.
  • The webcast is available at: www.cegedim.fr/webcast
    The fiscal 2022 results presentation is available:
    And on the Cegedim IR smartphone app, available at https://www.cegedim.fr/finance/profil/Pages/CegedimIR.aspx

Agendia Announces First Patient Enrolled in Prospective LESS Clinical Study, Sponsored by Unicancer, to De-escalate Endocrine Therapy in Women with Early Breast Cancer

Retrieved on: 
Wednesday, November 16, 2022

The study aims to enroll 696 patients via 45 sites within the French breast cancer intergroup Unicancer (UCBG) by October 2024.

Key Points: 
  • The study aims to enroll 696 patients via 45 sites within the French breast cancer intergroup Unicancer (UCBG) by October 2024.
  • Previous studies have shown patients with HR+/HER2- breast cancer with a MammaPrint Ultra Low result can have an excellent prognosis at 20 years with reduced endocrine therapy.
  • Through our partnership with Unicancer, we are expanding knowledge on the complexity of breast cancer and enabling further personalized treatments in cancer care.
  • Agendias singular focus on breast cancer facilitates continued investment in global research to unravel the intricacies of precision medicine and drive personalized treatment planning for women with breast cancer.

Cegedim: 1H 2022 Earnings

Retrieved on: 
Tuesday, September 20, 2022

The Data & marketing division posted like-for-like revenue growth of 11.8% in the first half of 2022.

Key Points: 
  • The Data & marketing division posted like-for-like revenue growth of 11.8% in the first half of 2022.
  • (1) Alternative performance indicator, for a definition and reconciliation of these figures, see point 3.6, note 2 of the 2022 Interim Financial Report.
  • On May 16, 2022, Cegedim Group and social protection companies Malakoff Humanis, Groupe VYV, and PRO BTP Groupe announced that they had finalized the strategic partnership they began negotiating on March 1, 2022.
  • 0.5 per share) in respect of fiscal year 2021 was approved at the General Shareholders Meeting on June 17, 2022, and paid in July 2022.

Cegedim : Growth picked up speed in Q2 2022

Retrieved on: 
Thursday, July 28, 2022

H1 2022 division revenues came to 145.6 million, up 3.0% like for like(1) compared with the same period in 2021.

Key Points: 
  • H1 2022 division revenues came to 145.6 million, up 3.0% like for like(1) compared with the same period in 2021.
  • H1 2022 division revenues came to 45.2 million, up 8.2% like for like(1) compared with the same period in 2021.
  • H1 2022 division revenues came to 50.0 million, up 11.8% like for like(1) compared with the same period in 2021.
  • there were no events or changes during Q2 2022 that would materially alter the Groups financial situation.

DGAP-News: Nantes University Hospital Doses First Patients with Eckert & Ziegler's Novel Ga-68 Imaging Agent PENTIXAFOR

Retrieved on: 
Monday, September 27, 2021

The Centre Hospitalier Universitaire de Nantes (CHU), the French university hospital serving the greater Nantes/Saint-Nazaire metropolitan area, has started to dose first patients with PENTIXAFOR, an innovative imaging compound for the initial staging of cancer patients with symptomatic multiple myelomas.

Key Points: 
  • The Centre Hospitalier Universitaire de Nantes (CHU), the French university hospital serving the greater Nantes/Saint-Nazaire metropolitan area, has started to dose first patients with PENTIXAFOR, an innovative imaging compound for the initial staging of cancer patients with symptomatic multiple myelomas.
  • To investigate the potential of PENTIXAFOR the CHU will recruit, on its own account, up to 45 patients in a so-called investigator-initiated study (ISS).
  • Given the potential of PENTIXAFOR for improved patient stratification, academic groups like CHU have decided to move ahead on their own and to test PENTIXAFOR right away.
  • To speed up the PENTIXAFOR marketing authorization, Eckert & Ziegler closely cooperates with such initiatives and supports them where feasible.

Six Major Valeo Innovations for Safer and Cleaner Mobility to be Presented at the IAA Mobility 2021

Retrieved on: 
Monday, July 26, 2021

PARIS, July 26, 2021 /PRNewswire/ -- Valeo will unveil six innovations - including a series of technologies that can create a "health shield" within the interior of a vehicle and charging stations suitable for all electric vehicles - at IAA Mobility in September. The technologies underscore Valeo's ongoing commitment to develop safer, cleaner and more diverse mobility.The IAA, for the first time in the show's history, will be held in Munich. It has been renamed IAA Mobility for the occasion. No longer promoted as just the annual forum for the global automotive industry, the IAA is also the place where the future of mobility takes shape. The Valeo innovations to be presented from Sept. 7 through Sept. 12 include: Automated Valet Parking: The feature - developed in collaboration with BMW - allows a vehicle to park itself in a parking lot.Valeo Drive4U: The Valeo Drive4U is a prototype autonomous car. It will drive in automated mode on open roads in and outside the city of Munich (on the Blue Lane) reaching Level 4 autonomy. It is exclusively equipped with Valeo sensors that are already in series production (LiDARs, cameras, radars, ultrasonic sensors etc.). This vehicle can handle urban and suburban traffic, traffic jams, intersections, traffic circles, traffic lights, pedestrian crossings and construction zones. It is equipped with two other safety-enhancing features: The Valeo Drive4U Locate system pinpoints the vehicle's location on the road with centimeter-level precision compared with a standard GPS system where the margin of error is as much as five meters. The Valeo MovePredict.ai system uses artificial intelligence to anticipate the movements of vulnerable people around the vehicle and brakes before they have even moved.This year has been historic for mobility with the launch of the first car in the world to reach Level 3 autonomy – equipped with Valeo's LiDAR technology. Level 3 autonomy can only be achieved using 3D LiDAR technology combined with a series of sensors. Advanced driver assistance systems (ADAS) are transforming mobility. Valeo is the world leader in this field with one-in-four new vehicles worldwide equipped with its technologies.Vital Signs Monitoring: Valeo takes a holistic approach to the challenge of safer mobility. The company is developing products to help the vehicle assess and avoid potential life-threatening situations while ensuring passengers travel in a healthy cabin environment.

Key Points: 
  • The technologies underscore Valeo's ongoing commitment to develop safer, cleaner and more diverse mobility.
  • It is exclusively equipped with Valeo sensors that are already in series production (LiDARs, cameras, radars, ultrasonic sensors etc.).
  • This vehicle can handle urban and suburban traffic, traffic jams, intersections, traffic circles, traffic lights, pedestrian crossings and construction zones.
  • Vital Signs Monitoring: Valeo takes a holistic approach to the challenge of safer mobility.